Sun Pharma said to be planning upgrades, new R&D facility at troubled Madhya Pradesh facility


Sun Pharmaceutical, India’s largest generics maker, is reportedly looking to make a “significant investment” at the troubled facility in Madhya Pradesh the company inherited when it acquired Ranbaxy Laboratories for $4 billion.

The Dewas site in Madhya Pradesh is one of four manufacturing facilities that were banned by the FDA while they were operating under the Ranbaxy flag.

The improvements at the site by Sun are reported to include a new R&D facility, liveMint reported. Sun recently signed a deal with the Indian government to work towards eradicating malaria.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Sun officials have repeatedly said following the Ranbaxy buyout last year that as they integrate the two companies they would also upgrade the four Ranbaxy plants in India that made the FDA banned list for data integrity problems and other issues.

In May, Sun said that it would be looking for the FDA to reinspect at least one of the plants by the end of the year.

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.